Not specified
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Job Category:
Health Care Provider
Process Scientist #11826BR
(This job is no longer available)
Grad Date

Not sure what types of jobs you are interested in?

Explore Jobs
Based on Your Education

Follow This Company

Job Description

Chemistry Regeneron Pharmaceuticals, Inc. is seeking a Process Scientist for our Rensselaer, New York location to support scientific investigations related to production processes for biological drugs. The position will perform protein purification and support scientific investigations related to downstream unit operations of biologics manufacturing processes. Perform protein stability study and microbial study, including bioburden clearance using small-scale chromatography column. Work within a team of Scientists and Associates to support activities to assure that scientific investigations are planned and coordinated cross-functionally and executed effectively. Conduct experiments in scale-down models using depends on experience or other experimental principals using GE AKTA systems.

Support the execution of an effective raw material use testing and control plan. Qualified applicants will have a Doctor of Philosophy degree in Chemical Engineering, Biochemistry or a related field, and 3 years of experience working in a purification sciences team. Must possess at least 3 years of experience with: protein separation techniques, experimental design, data analysis using advanced mathematical tools, including JMP, and protein stability & formulation. A qualified applicant will possess 3 years of experience with microbial study and complex raw material chemistry. Up to 25% international and domestic travel is required.


recblid 61bl7jqauxhzfkkno25pwlof9nlpup

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for the treatment of serious medical conditions. As of December 31, 2008, the Company had one marketed product: ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available for prescription in the United States for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold auto-inflammatory syndrome (FCAS) and muckle-wells syndrome (MWS) in adults and children aged 12 and older. Regeneron also has six clinical development programs, including three late-stage clinical programs. Its late-stage programs are aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group; VEGF Trap-Eye, which is being developed in eye diseases using intraocular delivery in collaboration with Bayer HealthCare LLC, and ARCALYST, which is being developed for the treatment of gout. (Source: 10-K)